Stockscreener 앱 받기
26.20
4.09%
1.03
시간 외 거래:
26.22
0.02
+0.08%
전일 마감가:
$25.17
열려 있는:
$26.01
하루 거래량:
69,689
Relative Volume:
0.64
시가총액:
$876.34M
수익:
-
순이익/손실:
-
주가수익비율:
-4.9533
EPS:
-5.2894
순현금흐름:
-
1주 성능:
+3.52%
1개월 성능:
+31.07%
6개월 성능:
-7.16%
1년 성능:
+0.00%
1일 변동 폭
$25.09
$26.44
1주일 범위
$24.43
$26.44
52주 변동 폭
$17.06
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
명칭
Spyglass Pharma Inc
전화
949-284-6904
주소
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
26.20 | 845.23M | 0 | 0 | 0 | -5.2894 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | H.C. Wainwright | Buy |
| 2026-03-03 | 개시 | Citigroup | Buy |
| 2026-03-03 | 개시 | Jefferies | Buy |
| 2026-03-03 | 개시 | Leerink Partners | Outperform |
| 2026-03-03 | 개시 | Stifel | Buy |
Spyglass Pharma Inc 주식(SGP)의 최신 뉴스
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - marketbeat.com
Spyglass Pharma (NASDAQ:SGP) Upgraded to "Moderate Buy" at Raymond James Financial - marketbeat.com
SpyGlass Pharma, Inc. (NASDAQ: SGP) Share Price, SGP Stock News, SGP Share Price & Updates - Kalkine
Raymond James initiates SpyGlass Pharma stock coverage with outperform rating - Investing.com
Q3 EPS Estimates for Spyglass Pharma Decreased by Analyst - marketbeat.com
SpyGlass Pharma Ord shs (Proposed) (SGP) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
SpyGlass Pharma Reports Q2 Financials, Provides Corporate Updates - VisionMonday.com
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
SpyGlass Pharma 2Q 2026: Net loss $(19.9)M, EPS $(0.59) — 10-Q Summary - TradingView
[10-Q] SpyGlass Pharma, Inc. Quarterly Earnings Report - Stock Titan
SpyGlass Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
SpyGlass Pharma reports $19.9M Q2 net loss, $234.2M cash and investments as of June 30, 2026 - TradingView
SpyGlass Pharma Q2 net loss widens on higher expenses - TradingView
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
SpyGlass Pharma Insiders Enjoying US$1.1m Appreciation On US$2.16m Investment - webull.com
SpyGlass Pharma (SGP) Rallies 3.08% to $24.41 as Ophthalmic Focus Draws Fresh BuyingLow Vol Factor - dars.gov.et
SpyGlass glaucoma trial enrollment remains on track for 2027 - Stock Titan
22,536,164 Common Stock of SpyGlass Pharma, Inc. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
SpyGlass Pharma (SGP) Gains 1.34% as Stock Tests Key Resistance LevelPoint of Control - dars.gov.et
SGP|SpyGlass Pharma Ord shs (Proposed)|Price:20.490|Chg%:-0.390 - TradingKey
Spyglass Pharma (NASDAQ:SGP) Shares Gap UpStill a Buy? - MarketBeat
SpyGlass Pharma, Inc. Revenue Breakdown – NASDAQ:SGP - TradingView
SpyGlass Pharma (SGP) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
SpyGlass Pharma (SGP) Drops 4.77% as Key Support Levels Are TestedFade Trade - dars.gov.et
SpyGlass Pharma (SGP) Dips Nearly 5%, Testing Key Support LevelsFundamentals - dars.gov.et
SpyGlass Pharma (SGP) Rallies 2.67%, Tests Key Resistance LevelDynamic Hedging - dars.gov.et
SGP Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains AbsentEarnings Miss Alert - dars.gov.et
SpyGlass Pharma Inc. (SGP) Q1 2026 Earnings: Wider-Than-Expected Loss Triggers Double-Digit Selloff - dars.gov.et
SpyGlass Pharma (SGP) Slips 1.64% as Stock Tests Key Support Around $18.19Runaway Gap - po-news-eg.net
SGP Q1 2026 Earnings: EPS Misses Estimates, Stock Edges HigherLong-Term Guidance - dars.gov.et
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Value Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Value Benchmark - marketscreener.com
SpyGlass Pharma (SGP) Registration Filing Summary - Quartr
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Growth Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 3000E Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell Microcap Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell Small Cap Completeness Index - marketscreener.com
SGP Forecast — Price Target — Prediction for 2027 - TradingView
Transcript : SpyGlass Pharma, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
SpyGlass Pharma, Inc. Actuals & Estimates (NASDAQ:SGP) - TradingView
Price to sales forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Enterprise value to revenue forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Price to book forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Price to earnings forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Enterprise value to EBIT forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Spyglass Pharma (SGP) Short Interest & Short Float | Updated Jun 2026 $SGP - MarketBeat
SpyGlass Pharma Inc. Q1 2026 Earnings: Wider-Than-Expected Loss Fails to Dampen Investor OptimismRevenue Miss Report - dars.gov.et
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P Global BMI Index - marketscreener.com
Spyglass Pharma Inc (SGP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):